Sublethal exposure to alpha radiation (223Ra dichloride) enhances various carcinomas' sensitivity to lysis by antigenspecific cytotoxic T lymphocytes through calreticulin-mediated immunogenic modulation

Oncotarget

Volumn 7, Issue 52, 2016, Pages 86937-86947

  Malamas, Anthony S ^a   Gameiro, Sofia R ^a   Knudson, Karin M ^a   Hodge, James W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Alpha radiation; Calreticulin; CTL mediated lysis; Immunogenic modulation; Radium 223

Indexed keywords

BRACHYURY ANTIGEN; CALRETICULIN; CARCINOEMBRYONIC ANTIGEN; K RAS PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MUCIN 1; PROTEIN P53; RADIUM CHLORIDE RA 223; TUMOR ANTIGEN; UNCLASSIFIED DRUG; CALRETICULIN, HUMAN; HLA ANTIGEN; RADIUM; RADIUM-223;

ALPHA RADIATION; ANTIGEN PRESENTATION; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER CELL LINE; CD8+ T LYMPHOCYTE; CELL MEDIATED CYTOTOXICITY; CELL SURFACE; CELL VIABILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ENDOPLASMIC RETICULUM STRESS; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VITRO STUDY; LUNG CANCER CELL LINE; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; CELL PROLIFERATION; CYTOTOXICITY; IMMUNOLOGY; NEOPLASM; PHYSIOLOGY; RADIATION RESPONSE; THERAPEUTIC USE; TUMOR CELL LINE;

ALPHA PARTICLES; CALRETICULIN; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOTOXICITY, IMMUNOLOGIC; DOSE-RESPONSE RELATIONSHIP, RADIATION; ENDOPLASMIC RETICULUM STRESS; HLA ANTIGENS; HUMANS; NEOPLASMS; RADIUM; T-LYMPHOCYTES, CYTOTOXIC;

EID: 85007492442     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.13520     Document Type: Article

References (44)

1. Brawley OW. Trends in prostate cancer in the United States. Journal of the National Cancer Institute Monographs. 2012; 2012:152-156
2. Body JJ, Casimiro S, Costa L. Targeting bone metastases in prostate cancer: improving clinical outcome. Nature reviews Urology. 2015; 12:340-356
3. Ahmadzadehfar H, Eppard E, Kurpig S, Fimmers R, Yordanova A, Schlenkhoff CD, Gartner F, Rogenhofer S, Essler M. Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer. Oncotarget. 2016; 7:12477-12488. doi: 10.18632/oncotarget.7245
4. Gartrell BA, Coleman R, Efstathiou E, Fizazi K, Logothetis CJ, Smith MR, Sonpavde G, Sartor O, Saad F. Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options. European urology. 2015; 68:850-858
5. Coleman R. Treatment of Metastatic Bone Disease and the Emerging Role of Radium-223. Seminars in nuclear medicine. 2016; 46:99-104
6. Saad F, Markus R, Goessl C. Targeting the receptor activator of nuclear factor-kappaB (RANK) ligand in prostate cancer bone metastases. BJU international. 2008; 101:1071-1075
7. Abou DS, Ulmert D, Doucet M, Hobbs RF, Riddle RC, Thorek DL. Whole-Body and Microenvironmental Localization of Radium-223 in Naive and Mouse Models of Prostate Cancer Metastasis. Journal of the National Cancer Institute. 2015 Dec 18; 108
8. Goyal J, Antonarakis ES. Bone-targeting radiopharmaceuticals for the treatment of prostate cancer with bone metastases. Cancer letters. 2012; 323:135-146
9. Sgouros G. Alpha-particles for targeted therapy. Advanced drug delivery reviews. 2008; 60:1402-1406
10. Lewington VJ. Bone-seeking radionuclides for therapy. Journal of nuclear medicine. 2005; 46 Suppl 1:38S-47S
11. Harrison MR, Wong TZ, Armstrong AJ, George DJ. Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease. Cancer management and research. 2013; 5:1-14
12. Nilsson S, Larsen RH, Fossa SD, Balteskard L, Borch KW, Westlin JE, Salberg G, Bruland OS. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clinical cancer research. 2005; 11:4451-4459
13. Sartor O, Maalouf B, CR H, Macklis R. Targeted use of alpha particles: current status in cancer therapeutics. J Nucl Med Radiat Ther. 2012; 3:136
14. Bruland OS, Nilsson S, Fisher DR, Larsen RH. High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities? Clinical cancer research. 2006; 12:6250s-6257s
15. Elgqvist J, Frost S, Pouget JP, Albertsson P. The potential and hurdles of targeted alpha therapy-clinical trials and beyond. Frontiers in oncology. 2014; 3:324
16. Coleman R, Aksnes AK, Naume B, Garcia C, Jerusalem G, Piccart M, Vobecky N, Thuresson M, Flamen P. A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease. Breast cancer research and treatment. 2014; 145:411-418
17. Parker CC. The role of bisphosphonates in the treatment of prostate cancer. BJU international. 2005; 95:935-938
18. Hodge JW, Garnett CT, Farsaci B, Palena C, Tsang KY, Ferrone S, Gameiro SR. Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death. International journal of cancer. 2013; 133:624-636
19. Hodge JW, Ardiani A, Farsaci B, Kwilas AR, Gameiro SR. The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors. Seminars in oncology. 2012; 39:323-339
20. Gameiro SR, Ardiani A, Kwilas A, Hodge JW. Radiation-induced survival responses promote immunogenic modulation to enhance immunotherapy in combinatorial regimens. Oncoimmunology. 2014; 3:e28643
21. Garnett CT, Palena C, Chakraborty M, Tsang KY, Schlom J, Hodge JW. Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer research. 2004; 64:7985-7994
22. Gameiro SR, Malamas AS, Bernstein MB, Tsang KY, Vassantachart A, Sahoo N, Tailor R, Pidikiti R, Guha CP, Hahn SM, Krishnan S, Hodge JW. Tumor Cells Surviving Exposure to Proton or Photon Radiation Share a Common Immunogenic Modulation Signature, Rendering Them More Sensitive to T Cell-Mediated Killing. International journal of radiation oncology, biology, physics. 2016; 95:120-130
23. Hobbs RF, Song H, Watchman CJ, Bolch WE, Aksnes AK, Ramdahl T, Flux GD, Sgouros G. A bone marrow toxicity model for Ra alpha-emitter radiopharmaceutical therapy. Physics in medicine and biology. 2012; 57:3207-3222
24. Takalkar A, Paryani B, Adams S, Subbiah V. Radium-223 dichloride therapy in breast cancer with osseous metastases. BMJ case reports. 2015
25. Gameiro SR, Jammeh ML, Wattenberg MM, Tsang KY, Ferrone S, Hodge JW. Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing. Oncotarget. 2014; 5:403-416. doi: 10.18632/oncotarget.1719
26. Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, Benci JL, Xu B, Dada H, Odorizzi PM, Herati RS, Mansfield KD, Patsch D, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015; 520:373-377
27. Derer A, Frey B, Fietkau R, Gaipl US. Immune-modulating properties of ionizing radiation: rationale for the treatment of cancer by combination radiotherapy and immune checkpoint inhibitors. Cancer immunology, immunotherapy: CII. 2016; 65:779-786
28. Hodge JW, Kwilas A, Ardiani A, Gameiro SR. Attacking malignant cells that survive therapy: Exploiting immunogenic modulation. Oncoimmunology. 2013; 2:e26937
29. Baidoo KE, Yong K, Brechbiel MW. Molecular pathways: targeted alpha-particle radiation therapy. Clinical cancer research. 2013; 19:530-537
30. Kim YS, Brechbiel MW. An overview of targeted alpha therapy. Tumour biology. 2012; 33:573-590
31. Hagemann UB, Wickstroem K, Wang E, Shea AO, Sponheim K, Karlsson J, Bjerke RM, Ryan OB, Cuthbertson AS. In Vitro and In Vivo Efficacy of a Novel CD33-Targeted Thorium-227 Conjugate for the Treatment of Acute Myeloid Leukemia. Molecular cancer therapeutics. 2016
32. Ardiani A, Gameiro SR, Kwilas AR, Donahue RN, Hodge JW. Androgen deprivation therapy sensitizes prostate cancer cells to T-cell killing through androgen receptor dependent modulation of the apoptotic pathway. Oncotarget. 2014; 5:9335-9348. doi: 10.18632/oncotarget.2429
33. Saad F, Carles J, Gillessen S, Heidenreich A, Heinrich D, Gratt J, Levy J, Miller K, Nilsson S, Petrenciuc O, Tucci M, Wirth M, Federhofer J, et al. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. The Lancet Oncology. 2016; 17:1306-1316
34. Kudo-Saito C, Schlom J, Camphausen K, Coleman CN, Hodge JW. The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors. Clinical cancer research. 2005; 11:4533-4544
35. Chakraborty M, Abrams SI, Coleman CN, Camphausen K, Schlom J, Hodge JW. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer research. 2004; 64:4328-4337
36. Chakraborty M, Gelbard A, Carrasquillo JA, Yu S, Mamede M, Paik CH, Camphausen K, Schlom J, Hodge JW. Use of radiolabeled monoclonal antibody to enhance vaccine-mediated antitumor effects. Cancer immunology, immunotherapy: CII. 2008; 57:1173-1183
37. Chakraborty M, Wansley EK, Carrasquillo JA, Yu S, Paik CH, Camphausen K, Becker M, Goeckler W, Schlom J, Hodge JW. Use of Samarium-153-EDTMP to modulate phenotype of tumor cells and enhance T-cell-mediated killing, Clinical cancer research. 2008; 14:4316-4325
38. Heery CR, Madan RA, Stein MN, Stadler WM, DiPaola RS, Rauckhorst M, Steinberg SM, Marte JL, Chen CC, Grenga I, Donahue RN, Jochems C, Dahut WL, et al. Samarium-153-EDTMP (Quadramet(R)) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trial. Oncotarget. 2016. doi: 10.18632/oncotarget.10883
39. Tsang KY, Zhu M, Nieroda CA, Correale P, Zaremba S, Hamilton JM, Cole D, Lam C, Schlom J. Phenotypic stability of a cytotoxic T-cell line directed against an immunodominant epitope of human carcinoembryonic antigen. Clinical cancer research. 1997; 3:2439-2449
40. Tsang KY, Zaremba S, Nieroda CA, Zhu MZ, Hamilton JM, Schlom J. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. Journal of the National Cancer Institute. 1995; 87:982-990
41. Tsang KY, Palena C, Gulley J, Arlen P, Schlom J. A human cytotoxic T-lymphocyte epitope and its agonist epitope from the nonvariable number of tandem repeat sequence of MUC-1. Clinical cancer research. 2004; 10:2139-2149
42. Jochems C, Tucker JA, Vergati M, Boyerinas B, Gulley JL, Schlom J, Tsang KY. Identification and characterization of agonist epitopes of the MUC1-C oncoprotein. Cancer immunology, immunotherapy: CII. 2014; 63:161-174
43. Tucker JA, Boyerinas B, Fallon J, Greiner JW, Palena C, Rodell TC, Schlom J, Tsang KY. Identification and characterization of a cytotoxic T-lymphocyte agonist epitope of brachyury, a transcription factor involved in epithelial to mesenchymal transition and metastasis. Cancer immunology, immunotherapy: CII. 2014; 63:1307-1317
44. Gameiro SR, Malamas AS, Tsang KY, Ferrone S, Hodge JW. Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells. Oncotarget. 2016; 7:7390-7402. doi: 10.18632/oncotarget.7180